Metabolic and Type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease

Experimental Neurology

Volumn 229, Issue 2, 2011, Pages 440-449

  Casteels, C ^a,b   Vandeputte, C ^a,b   Rangarajan, J R ^a   Dresselaers, T ^b   Riess, O ^c   Bormans, G ^b   Maes, F ^a   Himmelreich, U ^b   Nguyen, H ^c   Van Laere, K ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

18F MK 9470; Huntington disease; Pre symptomatic; Small animal PET; TgHD; Type 1 cannabinoid receptor

Indexed keywords

CANNABINOID 1 RECEPTOR; FLUORODEOXYGLUCOSE F 18; N [2 (3 CYANOPHENYL) 3 [4 (2 FLUORETHOXY)PHENYL] 1 METHYLPROPYL] 2 (5 METHYL 2 PYRIDYLOXY) 2 METHYLPROPONAMIDE F 18; RADIOLIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN LATERAL VENTRICLE; BRAIN SIZE; CAUDATE NUCLEUS; COGNITION; CONTROLLED STUDY; GENOTYPE; GLOBUS PALLIDUS; GLUCOSE METABOLISM; HUNTINGTON CHOREA; IN VIVO STUDY; MALE; MOLECULAR EVOLUTION; MOLECULAR IMAGING; MOTOR PERFORMANCE; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RAT; RECEPTOR BINDING; SENSORIMOTOR CORTEX; TRANSGENIC RAT;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN; BRAIN MAPPING; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; GLUCOSE; HUNTINGTON DISEASE; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MAZE LEARNING; MEMORY; MOTOR SKILLS; NEURONS; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; RECEPTOR, CANNABINOID, CB1; STATISTICS, NONPARAMETRIC;

EID: 79956092492     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.03.014     Document Type: Article

References (49)

1. Antonini A., Leenders K.L., Spiegel R., Meier D., Vontobel P., Weigell-Weber M., Sanchez-Pernaute R., de Yebenez J.G., Boesiger P., Weindl A., Maguire R.P. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996, 119(Pt 6):2085-2095.
2. Baquet Z.C., Gorski J.A., Jones K.R. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J. Neurosci. 2004, 24:4250-4258.
3. Barrero F.J., Ampuero I., Morales B., Vives F., de Dios Luna Del Castillo J., Hoenicka J., Garcia Y.J. Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics J. 2005, 5:135-141.
4. Berrendero F., Romero J., Garcia-Gil L., Suarez I., De la Cruz P., Ramos J.A., Fernandez-Ruiz J.J. Changes in cannabinoid receptor binding and mRNA levels in several brain regions of aged rats. Biochim. Biophys. Acta 1998, 1407:205-214.
5. Bisogno T., Martire A., Petrosino S., Popoli P., Di Marzo V. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease. Neurochem. Int. 2008, 52:307-313.
6. Blazquez C., Chiarlone A., Sagredo O., Aguado T., Pazos M.R., Resel E., Palazuelos J., Julien B., Salazar M., Borner C., Benito C., Carrasco C., ez-Zaera M., Paoletti P., az-Hernandez M., Ruiz C., Sendtner M., Lucas J.J., de Yebenes J.G., Marsicano G., Monory K., Lutz B., Romero J., Alberch J., Gines S., Kraus J., Fernandez-Ruiz J., Galve-Roperh I., Guzman M. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 2011, 134:119-136.
7. Burns H.D., Van Laere K., Sanabria-Bohorquez S., Hamill T.G., Bormans G., Eng W.S., Gibson R., Ryan C., Connolly B., Patel S., Krause S., Vanko A., Van Hecken A., Dupont P., De Lepeleire I., Rothenberg P., Stoch S.A., Cote J., Hagmann W.K., Jewell J.P., Lin L.S., Liu P., Goulet M.T., Gottesdiener K., Wagner J.A., de Hoon J., Mortelmans L., Fong T.M., Hargreaves R.J. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:9800-9805.
8. Casteels C., Lauwers E., Baitar A., Bormans G., Baekelandt V., Van Laere K. In vivo type 1 cannabinoid receptor mapping in the 6-hydroxydopamine lesion rat model of Parkinson's disease. Brain Res. 2010, 1316:153-162.
9. Casteels C., Martinez E., Bormans G., Camon L., de Vera N., Baekelandt V., Planas A.M., Van Laere K. Type 1 cannabinoid receptor mapping with [(18)F]MK-9470 PET in the rat brain after quinolinic acid lesion: a comparison to dopamine receptors and glucose metabolism. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:2354-2363.
10. Casteels C., Vermaelen P., Nuyts J., Van Der Linden A., Baekelandt V., Mortelmans L., Bormans G., Van Laere K. Construction and evaluation of multitracer small-animal PET probabilistic atlases for voxel-based functional mapping of the rat brain. J. Nucl. Med. 2006, 47:1858-1866.
11. Denovan-Wright E.M., Robertson H.A. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience 2000, 98:705-713.
12. Dowie M.J., Bradshaw H.B., Howard M.L., Nicholson L.F., Faull R.L., Hannan A.J., Glass M. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. Neuroscience 2009, 163:456-465.
13. Dowie M.J., Howard M.L., Nicholson L.F., Faull R.L., Hannan A.J., Glass M. Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice. Neuroscience 2010, 170:324-336.
14. Glass M., Dragunow M., Faull R.L. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000, 97:505-519.
15. Goffin K., Bormans G., Casteels C., Bosier B., Lambert D.M., Grachev I.D., Van Paesschen W., Van Laere K. An in vivo [(18)F]MK-9470 microPET study of type 1 cannabinoid receptor binding in Wistar rats after chronic administration of valproate and levetiracetam. Neuropharmacology 2008, 54:1103-1106.
16. Goutopoulos A., Makriyannis A. From cannabis to cannabinergics: new therapeutic opportunities. Pharmacol. Ther. 2002, 95:103-117.
17. Hayden M.R., Hewitt J., Stoessl A.J., Clark C., Ammann W., Martin W.R. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease. Neurology 1987, 37:1441-1447.
18. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:1932-1936.
19. Hockly E., Cordery P.M., Woodman B., Mahal A., van Dellen A., Blakemore C., Lewis C.M., Hannan A.J., Bates G.P. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann. Neurol. 2002, 51:235-242.
20. Holter S.M., Tzschentke T.M., Schmidt W.J. Effects of amphetamine, morphine and dizocilpine (MK-801) on spontaneous alternation in the 8-arm radial maze. Behav. Brain Res. 1996, 81:53-59.
21. Joshi P.R., Wu N.P., Andre V.M., Cummings D.M., Cepeda C., Joyce J.A., Carroll J.B., Leavitt B.R., Hayden M.R., Levine M.S., Bamford N.S. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J. Neurosci. 2009, 29:2414-2427.
22. Katona I., Freund T.F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat. Med. 2008, 14:923-930.
23. Koopmans G.C., Deumens R., Brook G., Gerver J., Honig W.M., Hamers F.P., Joosten E.A. Strain and locomotor speed affect over-ground locomotion in intact rats. Physiol. Behav. 2007, 92:993-1001.
24. Kuhn A., Goldstein D.R., Hodges A., Strand A.D., Sengstag T., Kooperberg C., Becanovic K., Pouladi M.A., Sathasivam K., Cha J.H., Hannan A.J., Hayden M.R., Leavitt B.R., Dunnett S.B., Ferrante R.J., Albin R., Shelbourne P., Delorenzi M., Augood S.J., Faull R.L., Olson J.M., Bates G.P., Jones L., Luthi-Carter R. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet. 2007, 16:1845-1861.
25. Lastres-Becker I., Berrendero F., Lucas J.J., Martin-Aparicio E., Yamamoto A., Ramos J.A., Fernandez-Ruiz J.J. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease. Brain Res. 2002, 929:236-242.
26. Lione L.A., Carter R.J., Hunt M.J., Bates G.P., Morton A.J., Dunnett S.B. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J. Neurosci. 1999, 19:10428-10437.
27. Luesse H.G., Schiefer J., Spruenken A., Puls C., Block F., Kosinski C.M. Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus. Behav. Brain Res. 2001, 126:185-195.
28. Maes F., Collignon A., Vandermeulen D., Marchal G., Suetens P. Multimodality image registration by maximization of mutual information. IEEE Trans. Med. Imaging 1997, 16:187-198.
29. Magistretti P.J. Neuron-glia metabolic coupling and plasticity. J. Exp. Biol. 2006, 209:2304-2311.
30. McCaw E.A., Hu H., Gomez G.T., Hebb A.L., Kelly M.E., Denovan-Wright E.M. Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur. J. Biochem. 2004, 271:4909-4920.
31. Naver B., Stub C., Moller M., Fenger K., Hansen A.K., Hasholt L., Sorensen S.A. Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. Neuroscience 2003, 122:1049-1057.
32. Nguyen H.P., Kobbe P., Rahne H., Worpel T., Jager B., Stephan M., Pabst R., Holzmann C., Riess O., Korr H., Kantor O., Petrasch-Parwez E., Wetzel R., Osmand A., von Horsten S. Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease. Hum. Mol. Genet. 2006, 15:3177-3194.
33. Noda A., Takamatsu H., Minoshima S., Tsukada H., Nishimura S. Determination of kinetic rate constants for 2-[18F]fluoro-2-deoxy-d-glucose and partition coefficient of water in conscious macaques and alterations in aging or anesthesia examined on parametric images with an anatomic standardization technique. J. Cereb. Blood Flow Metab. 2003, 23:1441-1447.
34. Richfield E.K., Herkenham M. Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann. Neurol. 1994, 36:577-584.
35. Romero J., Berrendero F., Garcia-Gil L., De la Cruz P., Ramos J.A., Fernandez-Ruiz J.J. Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35S]guanylyl-5'O-(thio)-triphosphate binding in the basal ganglia of aged rats. Neuroscience 1998, 84:1075-1083.
36. Sanabria-Bohorquez S.M., Hamill T.G., Goffin K., De Lepeleire I., Bormans G., Burns H.D., Van Laere K. Kinetic analysis of the cannabinoid-1 receptor PET tracer [(18)F]MK-9470 in human brain. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:920-933.
37. Solowij N., Michie P.T. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?. J. Psychiatry Neurosci. 2007, 32:30-52.
38. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983.
39. Toyama H., Ichise M., Liow J.S., Modell K.J., Vines D.C., Esaki T., Cook M., Seidel J., Sokoloff L., Green M.V., Innis R.B. Absolute quantification of regional cerebral glucose utilization in mice by 18F-FDG small animal PET scanning and 2-14C-DG autoradiography. J. Nucl. Med. 2004, 45:1398-1405.
40. van Dellen A., Blakemore C., Deacon R., York D., Hannan A.J. Delaying the onset of Huntington's in mice. Nature 2000, 404:721-722.
41. Van Laere K., Casteels C., Dhollander I., Goffin K., Grachev I., Bormans G., Vandenberghe W. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J. Nucl. Med. 2010, 51:1413-1417.
42. Van Laere K.J., Versijpt J., Koole M., Vandenberghe S., Lahorte P., Lemahieu I., Dierckx R.A. Experimental performance assessment of SPM for SPECT neuroactivation studies using a subresolution sandwich phantom design. Neuroimage 2002, 16:200-216.
43. Vandeputte C., Taymans J.M., Casteels C., Coun F., Ni Y., Van Laere K., Baekelandt V. Automated quantitative gait analysis in animal models of movement disorders. BMC Neurosci. 2010, 9:11-92.
44. von Horsten S., Schmitt I., Nguyen H.P., Holzmann C., Schmidt T., Walther T., Bader M., Pabst R., Kobbe P., Krotova J., Stiller D., Kask A., Vaarmann A., Rathke-Hartlieb S., Schulz J.B., Grasshoff U., Bauer I., Vieira-Saecker A.M., Paul M., Jones L., Lindenberg K.S., Landwehrmeyer B., Bauer A., Li X.J., Riess O. Transgenic rat model of Huntington's disease. Hum. Mol. Genet. 2003, 12:617-624.
45. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44:559-577.
46. Walhovd K.B., Fjell A.M., Reinvang I., Lundervold A., Dale A.M., Eilertsen D.E., Quinn B.T., Salat D., Makris N., Fischl B. Effects of age on volumes of cortex, white matter and subcortical structures. Neurobiol. Aging 2005, 26:1261-1270.
47. Wang X., Sarkar A., Cicchetti F., Yu M., Zhu A., Jokivarsi K., Saint-Pierre M., Brownell A.L. Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease. J. Neurol. Sci. 2005, 231:57-66.
48. Wooley C.M., Xing S., Burgess R.W., Cox G.A., Seburn K.L. Age, experience and genetic background influence treadmill walking in mice. Physiol. Behav. 2009, 96:350-361.
49. Young A.B., Penney J.B., Starosta-Rubinstein S., Markel D., Berent S., Rothley J., Betley A., Hichwa R. Normal caudate glucose metabolism in persons at risk for Huntington's disease. Arch. Neurol. 1987, 44:254-257.